First Committee Recommends Approval of Takeda’s Anti-Obesity Drug OBLEAN, Other Products

August 26, 2013
The Pharmaceutical Affairs and Food Sanitation Council’s (PAFSC) First Committee on Drugs on August 22 recommended approval of new drugs including Takeda Pharmaceutical’s anti-obesity drug OBLEAN Tablets 120 mg (cetilistat). OBLEAN is a lipase inhibitor which is effective in reducing...read more